Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.62 |
| ▸ | F10 | P00742 | 6/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823359 | 0.82 | GRM2 (0.66) | GRM2 | |
| SCHEMBL2823488 | 0.79 | GRM2 (0.61) | GRM2 | |
| SCHEMBL13051735 | 0.78 | GRM2 (0.69) | GRM2 | |
| SCHEMBL2825981 | 0.77 | GRM2 (1.00) | GRM2 | |
| SCHEMBL14723583 | 0.75 | F10 (0.64) | GRM2F10ITGB3ITGA2BPRSS1 | |
| SCHEMBL14722389 | 0.75 | F10 (0.64) | GRM2F10ITGB3ITGA2BPRSS1 | |
| SCHEMBL4450958 | 0.74 | GRM2 (0.61) | GRM2F10 | |
| SCHEMBL592438 | 0.73 | GRM2 (0.48) | GRM2F10ITGB3ITGA2BPRSS1 | |
| SCHEMBL592440 | 0.73 | GRM2 (0.48) | GRM2F10ITGB3ITGA2BPRSS1 | |
| SCHEMBL2827706 | 0.72 | GRM2 (0.74) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | claimed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2244576-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094265-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK & CO., INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRM1 | GRM2 1/4885F10 4571/4885ITGB3 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.